Opb-201

Phase 1

OOutpace Bio, Inc.

Opb-201 is one of 20 therapeutic programs targeting Endometrial Carcinoma. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

Endometrial CarcinomaNot yet recruiting

Endometrial CarcinomaPhase 1

Not yet recruiting

Competition

Competitive Landscape

21 competitors in Endometrial Carcinoma

#DrugCompanyPhaseTrials

Lynparza

AstraZeneca

Approved

1 2

Taxol

Teva

Phase 3

6 3

Keytruda

Merck & Co.

Phase 3

4 4

IC-Green

Megace

3 6

Depo-Provera

Eli Lilly

Phase 3

1 7

Afinitor

Novartis

Phase 2

1 8

Kisqali

Novartis

Phase 2

1 9

Femara

Novartis

Phase 2

1 10

Trodelvy

Gilead

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2030

Phase 1Not yet recruiting

Endometrial Carcinoma

NCT07664735

Clinical

Trials by Indication[1]

Endometrial Carcinoma1 trial

A Phase 1a/b Study to Evaluate the Safety and Efficacy of OPB 201, an Autologous PReferentially Expressed Antigen of MElanoma (PRAME) T Cell Receptor (TCR) T Cell Therapy in Recurrent Endometrial and Platinum-resistant Ovarian Cancer.

Not yet recruiting·OOutpace Bio, Inc.·Phase 1·NCT07664735·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Opb-201. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Opb-201. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Outpace Bio, Inc. company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 1[1]
Company: OOutpace Bio, Inc.

Opb-201

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2030

Trials by Indication[1]

Endometrial Carcinoma1 trial

References

Drug Info

Quick Facts

Related News